West Pharmaceutical Services Inc.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $3.07B | $2.89B | $2.82B | $2.84B | $2.84B | $2.05B | $1.77B |
| Service | — | — | — | $942.5M | $949.7M | $805.6M | $591.0M | $531.0M |
| Product | — | — | — | $1.88B | $1.89B | $2.04B | $1.46B | $1.23B |
| Cost of Revenue | — | $1.97B | $1.89B | $1.82B | $1.75B | $1.66B | $1.38B | $1.23B |
| Gross Profit | — | $1.10B | $998.5M | $1.13B | $1.14B | $1.18B | $767.8M | $605.7M |
| Gross Margin | — | 35.9% | 34.5% | 40.0% | 40.0% | 41.4% | 37.4% | 34.3% |
| Operating Expenses | ||||||||
| Research & Development | — | $74.3M | $69.1M | $68.4M | $58.5M | $52.8M | $46.9M | $38.9M |
| SG&A Expense | — | $393.6M | $338.5M | $353.4M | $316.9M | $362.8M | $302.0M | $272.7M |
| Operating Income | — | $584.9M | $569.9M | $676.0M | $734.0M | $752.3M | $406.9M | $296.6M |
| Operating Margin | — | 19.0% | 19.7% | 23.9% | 25.8% | 26.5% | 19.8% | 16.8% |
| Interest Expense | — | $15.1M | $16.2M | $9.0M | $7.9M | $8.2M | $8.2M | $8.5M |
| Pretax Income | — | $600.9M | $585.5M | $698.0M | $679.9M | $748.9M | $401.3M | $291.8M |
| Income Tax Expense | — | $121.6M | $107.5M | $122.3M | $114.7M | $107.2M | $72.5M | $59.0M |
| Net Income | — | $493.7M | $492.7M | $593.4M | $585.9M | $661.8M | $346.2M | $241.7M |
| Net Margin | — | 16.1% | 17.0% | 21.0% | 20.6% | 23.3% | 16.8% | 13.7% |
| EPS (Basic) | — | $6.83 | $6.75 | $7.98 | $7.87 | $8.89 | $4.68 | $3.27 |
| EPS (Diluted) | — | $6.79 | $6.69 | $7.88 | $7.73 | $8.67 | $4.57 | $3.21 |
| Shares Outstanding (Basic) | 72.0M | 72.3M | 73.0M | 74.3M | 74.4M | 74.4M | 73.9M | 74.0M |
| Shares Outstanding (Diluted) | 72.0M | 72.7M | 73.7M | 75.3M | 75.8M | 76.3M | 75.8M | 75.4M |
| Dividends Per Share | — | $0.86 | $0.82 | $0.78 | $0.74 | $0.70 | $0.66 | $0.62 |